Core Insights - Quantum-Si is focusing on the development and commercial readiness of its Proteus platform, with an expected launch at the end of 2026, which will impact near-term revenue [4][6][19] Financial Performance - For the full year 2025, Quantum-Si reported revenue of $2.4 million, with a gross profit of $1.2 million and a gross margin of 47% [15] - The company ended 2025 with $215.8 million in cash and equivalents, and for 2026, it projects approximately $1 million in revenue, with adjusted operating expenses capped at $98 million and cash usage at $93 million [5][18][19] Strategic Initiatives - The company has expanded its instrument acquisition options, securing 17 new customers across academic labs, pharma, and biotech, which helps in accessing key opinion leaders [2][6] - Quantum-Si is building a publication pipeline to demonstrate broader applications of its technology, with five manuscripts submitted in 2025 and three new releases in early 2026 [1][6] Product Development - The Proteus platform is expected to launch with a list price of $425,000, and the company is currently focusing on direct capital purchases for this product [8][10] - The company has made progress in its prototype systems, with successful internal deployments for R&D and plans for further manufacturing and delivery of additional instruments [11] Market Positioning - Quantum-Si is targeting higher consumable utilization rates and repeat ordering patterns through new applications in clinical proteomics and rapid pathogen detection [7][6] - The company is also exploring partnership opportunities to enhance its offerings, including artificial intelligence tools for deeper insights from protein sequencing data [7]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $451,000, with full-year revenue at $2.4 million, reflecting a gross profit of $1.2 million and a gross margin of 47% for the year [20][21] - Q4 gross margin was 27%, impacted by a higher proportion of consumable revenue compared to hardware sales [20] - Total operating expenses for Q4 2025 were $21.2 million, down from $31.3 million in Q4 2024, with adjusted operating expenses at $18.3 million compared to $26.7 million in the prior year [21][22] Business Line Data and Key Metrics Changes - The company reported a focus on consumable revenue, with expectations of a more than 25% increase in the number of consumable kits run by customers in 2026 [29] - The placement program for instruments has secured 17 new customers, enhancing access to key opinion leaders in the market [6][7] Market Data and Key Metrics Changes - The company anticipates modest capital sales in 2026 due to a focus on preparing the market for the Proteus launch, which is expected at the end of 2026 [5][10] - The NIH funding environment has shown some improvement, which may positively impact customer capital expenditures [49] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength as its corporate priorities for 2025 [4][18] - The focus for 2026 is on developing the market for Proteus, with a deliberate strategy to prioritize long-term platform adoption over short-term revenue maximization [24][26] Management's Comments on Operating Environment and Future Outlook - Management views 2026 as a transition year, with expectations of limited capital sales and a focus on consumable revenue [5][24] - The company is committed to maintaining fiscal discipline while ensuring core strategic initiatives are funded appropriately [19][26] Other Important Information - The list price for Proteus has been set at $425,000, aimed at balancing premium value with accessibility for potential customers [11][78] - The company has a strong balance sheet with $215.8 million in cash and investments, allowing for strategic execution into 2028 [23][25] Q&A Session Summary Question: What are the trends in consumables within the installed base? - Management noted a consistent purchase rate from customers, with expectations of a more than 25% increase in consumable kits run by customers in 2026 [29] Question: Should we expect very few placements in 2026 with most revenue from consumables? - Management confirmed that revenue will primarily come from consumables and services, with limited capital equipment sales anticipated [31][32] Question: How should we think about the launch curve for Proteus? - Management indicated that existing Platinum users will likely transition to Proteus, while new customers may adopt at varying rates based on application availability and financial incentives [34][35] Question: Does the $98 million in guidance for operating expenses include stock compensation? - Management clarified that the adjusted operating expense number excludes stock-based compensation, focusing on cash-oriented expenses [41] Question: Is there confidence in the price point for Proteus based on customer feedback? - Management stated that the price point was released to assist customers in capital planning, with no secured orders yet but positive feedback from discussions with potential customers [45][46] Question: Will Proteus be available through leasing or rental options? - Currently, the company plans to launch Proteus with direct capital sales only, with potential for other acquisition models to be evaluated based on market feedback [81]